Literature DB >> 11740707

Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed.

Mijke A Breukels1, Els Jol-van der Zijde, Maarten J D van Tol, Ger T Rijkers.   

Abstract

Haemophilus influenzae type b (Hib) conjugate vaccines are extremely effective in protecting infants and children from invasive Hib infections; however, vaccine failures do occur. The anti-Hib antibody production was studied both quantitatively and qualitatively in 12 patients who experienced Hib failure, all of whom had normal serum immunoglobulin concentrations and all of whom were without clinical risk factors for invasive Hib disease. Both anti-Hib antibody concentration and immunoglobulin-G2 anti-Hib antibody avidity were significantly lower in patients who experienced Hib failure, at onset of disease and after reconvalescence, when compared with controls. This finding suggests that the patients who developed invasive Hib disease--despite having received 3-4 Hib conjugate vaccinations--were inadequately primed by these vaccinations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740707     DOI: 10.1086/338259

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Troy J Kemp; Carolina Porras; Ligia A Pinto
Journal:  Mol Cell Probes       Date:  2012-01-18       Impact factor: 2.365

2.  Peptide ligand-based ELISA reagents for antibody detection.

Authors:  Ewa Heyduk; Rachel Hickey; Nicola Pozzi; Tomasz Heyduk
Journal:  Anal Biochem       Date:  2018-08-18       Impact factor: 3.365

3.  Avidity determinations for Haemophilus influenzae Type b anti-polyribosylribitol phosphate antibodies.

Authors:  Sandra Romero-Steiner; Patricia F Holder; Patricia Gomez de Leon; Willie Spear; Thomas W Hennessy; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

4.  Functional T-cell deficiency in adolescents who experience serogroup C meningococcal disease despite receiving the meningococcal serogroup C conjugate vaccine.

Authors:  Rachel A Foster; Jennifer Carlring; Andrew Lees; Ray Borrow; Mary Ramsay; Ed Kacsmarski; Elizabeth Miller; Michael W McKendrick; Andrew W Heath; Robert C Read
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

5.  Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom.

Authors:  Dominic F Kelly; E Richard Moxon; Ly-Mee Yu; Andrew J Pollard
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

6.  Immunoglobulin G avidities in infants in Mexico after primary immunization with three doses of polyribosylribitol phosphate-tetanus toxoid Haemophilus influenzae type b vaccine.

Authors:  Patricia Gómez-de-León; F Javier Díaz-García; Alberto Villaseñor-Sierra; Jorge Segura; Martha I Carranza; José Luis Arredondo-Garcia; José Ignacio Santos
Journal:  Clin Vaccine Immunol       Date:  2008-04-16

7.  Enhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery.

Authors:  Stefan Fernandez; Emily D Cisney; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

8.  Molecular epidemiology of Haemophilus influenzae type b isolated from children with clinical cases of conjugate vaccine failures.

Authors:  José Campos; Belén Aracil; Federico Román; María Pérez-Vázquez
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

9.  High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria.

Authors:  Sreenivasulu B Reddy; Robin F Anders; James G Beeson; Anna Färnert; Fred Kironde; Sharon Kühlman Berenzon; Mats Wahlgren; Sara Linse; Kristina E M Persson
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

10.  How Should Antibodies against P. falciparum Merozoite Antigens Be Measured?

Authors:  Sriwipa Chuangchaiya; Kristina E M Persson
Journal:  J Trop Med       Date:  2013-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.